- $20.32m
- -$39.16m
- $48.82m
- 59
- 99
- 25
- 64
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.34 | ||
| Price to Tang. Book | 0.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.28 | ||
| EV to EBITDA | -2.41 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 22.52% | ||
| Return on Equity | 36.8% | ||
| Operating Margin | 21.86% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.92 | 27.76 | 34.8 | 40.7 | 48.82 | 65.39 | 6.25 | 97.56% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML. ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. It targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP).
Directors
- Christine White NEC (69)
- Daniel Gold CEO (67)
- David Urso COO (57)
- Yomara Gomez-Naiden SVP
- Alejandro Ricart SVP
- Richard Ghalie OTH (64)
- Sujay Kango DRC (57)
- Charles Baltic IND (60)
- Cheryl Cohen IND (55)
- Frederick Driscoll IND (71)
- Nicholas Glover IND (52)
- Tamar Howson IND (73)
- Thomas Reynolds IND (62)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 1st, 2000
- Public Since
- December 18th, 2003
- No. of Shareholders
- 360
- No. of Employees
- 46
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 6,662,857
- Address
- 11455 El Camino Real, Suite 250, SAN DIEGO, 92130
- Web
- https://www.meipharma.com/
- Phone
- +1 8583697100
- Auditors
- BDO USA, LLP
Upcoming Events for MEIP
Q4 2024 MEI Pharma Inc Earnings Release
Similar to MEIP
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the MEI Pharma share price?
As of Today at 19:14 UTC, shares in MEI Pharma are trading at $3.05. This share price information is delayed by 15 minutes.
How has the MEI Pharma share price performed this year?
Shares in MEI Pharma last closed at $3.05 and the price had moved by -23.16% over the past 365 days. In terms of relative price strength the MEI Pharma share price has underperformed the S&P500 Index by -37.18% over the past year.
What are the analyst and broker recommendations for MEI Pharma?
The overall consensus recommendation for MEI Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the MEI Pharma dividend yield?
MEI Pharma does not currently pay a dividend.
Does MEI Pharma pay a dividend?
MEI Pharma does not currently pay a dividend.
When does MEI Pharma next pay dividends?
MEI Pharma does not currently pay a dividend.
How do I buy MEI Pharma shares?
To buy shares in MEI Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of MEI Pharma?
As of the previous close price of $3.05, shares in MEI Pharma had a market capitalisation of $20.32m.
Where are MEI Pharma shares listed?
Here are the trading details for MEI Pharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MEIP
What kind of share is MEI Pharma?
Based on an overall assessment of its quality, value and momentum MEI Pharma is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a MEI Pharma share price forecast for 2024?
The analyst consensus target price for shares in MEI Pharma is $23.00. That is 654.1% above the last closing price of $3.05.
Analysts covering MEI Pharma currently have a consensus Earnings Per Share (EPS) forecast of $3.29 for the next financial year.
What is the trend in the MEI Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MEI Pharma. Over the past six months, its share price has underperformed the S&P500 Index by -53.64%.
As of the last closing price of $3.05, shares in MEI Pharma were trading -38.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the MEI Pharma PE Ratio?
The MEI Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of MEI Pharma?
MEI Pharma's management team is headed by:
- Christine White - NEC
- Daniel Gold - CEO
- David Urso - COO
- Yomara Gomez-Naiden - SVP
- Alejandro Ricart - SVP
- Richard Ghalie - OTH
- Sujay Kango - DRC
- Charles Baltic - IND
- Cheryl Cohen - IND
- Frederick Driscoll - IND
- Nicholas Glover - IND
- Tamar Howson - IND
- Thomas Reynolds - IND